21
Dec
2017

How Did BioMarin Make It? The Long Run Podcast With Daniel Levine & Dan Maher

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

A Two-Pronged Attack on Cancer: Claire Mazumdar on The Long Run
Finding Therapies in Long Non-Coding RNA: John Rinn on The Long Run
A New and Old Idea for Cardiovascular Disease & Diabetes: Ethan Weiss & Josh Lehrer on The Long Run
Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run